世卫首席科学家:不必对阿斯利康暂停新冠疫苗测试过度泄气
对於英国阿斯利康与牛津大学共同研发的新冠疫苗暂停第三阶段人体测试,世界卫生组织首席科学家Soumya Swaminathan认为不必过度泄气,因类似事件会发生。她指这是正常测试程序,亦为良好临床测试行为,因安全是重中之重。她又认为这是对所有人的警醒,意识到研究会有起伏,临床研发会有起伏,并需要作好预备。她称所有人希望测试可以恢复,但要视乎很多因素,并在等候了解到底发生甚麽情况。
阿斯利康研发的疫苗为目前三款正进行最後阶段测试的新冠疫苗之一。辉瑞及Moderna的疫苗亦已在7月底开始测最後阶段临床测试。
Swaminathan指,疫苗最後阶段测试至有中期结果一般需时至少6个月,预期新冠疫苗有可能年底得知测试结果,其後须经监管机构检视结果及发准照。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.